United States of America, As Represented by the Secretary of Agriculture

Zoetis Services LLC

University of Connecticut

Lawrence Livermore National Security, LLC

Luis Leandro Rodriguez

Aida Elizabeth Rieder

Peter William Krug

Paul Joseph Dominowski

John Morgan Hardham

Cyril Gay

James Alan Jackson

Paul D Hoeprich

Teresa B De Los Santos

Fayna C Diaz-San Segundo

Devendra Rai

Jason R Hollister

Sabena Uddowla

Manuel V Borca

Vivian O'Donnell

Cyril Gerard Gay

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

Foot-and-mouth disease vaccine

Genetically engineered Foot and Mouth Disease Virus (FMDV) and related engineered proteins and polynucleotides, nanolipoprotein particles, compositions, methods and systems are described. The genetically engineered FMDV is modified by the strategic insertion of a protein tag into select regions of the FMDV genome which encode viral proteins that are exposed on the surface of the FMDV viral capsid. The inserted protein tag is displayed as a decoration or attachment on the viral capsid surface.

Genetically engineered foot and mouth disease virus and related proteins, polynucleotides, compositions, methods and systems

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 &#x3bc;g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

Genetically engineered Foot and Mouth Disease Virus and related proteins, polynucleotides, compositions, methods and systems

Compositions for prevention of Foot and Mouth Disease (FM D) are provided, comprising an antigen component in the amount equivalent to 0.5-20 &#x3bc;g FM D virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FM D persistence are also provided.

We have developed an ASFV Georgia strain adapted to grow in Vero cell line. The resulting virus, ASF-GVAV, efficiently grows in Vero cells although it still is able to significantly replicate in primary cell cultures of swine macrophages. ASF-GVAV virus was successfully used as parental virus to develop several recombinant ASF viruses. The development of an ASFV adapted to grow in an established cell line is a significant advance for research and development of vaccine candidate strains using genetic manipulation based in the process of homologous recombination. The GVAVS can be utilized as a basis for large scale production of ASF vaccines.

African swine fever virus georgia strain adapted to efficiently grow in the vero cell line

We have generated novel molecularly marked FMDV ALL3Dand ALL3B3Dvaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dand 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live ALL3D. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.

Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host

Growing community of inventors

Clinton, CT, United States of America

Luis Leandro Rodriguez